Condition
Advanced Malignant Pleural Mesothelioma|MPM
Estimated Enrollment: 12
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: OCOG-2012-DOVE-M
Study First Received: January 9, 2013
Last Updated: September 16, 2015
Estimated Primary Completion Date: June 2015
Primary Outcome Measures:
Progression Free Survival (PFS)|Objective Response Rate (ORR)|Stable disease rate/disease control rate (ORR + SD)|Duration of response / stable disease|Overall survival (OS)|Biomarker assessments using tissue and plasma samples, and imaging.|Safety and tolerability
Sponsors and Collaborators:
Ontario Clinical Oncology Group (OCOG)|Novartis Pharmaceuticals
Website Link: https://ClinicalTrials.gov/show/NCT01769547
